European Companies Search Engine

Quick Search Power Search
Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

4 EU fundings (total €190,498): 733273 - Optimalvax - Optimizing a Deployable High Efficacy Malaria Vaccine … BdlYear 2017 Financial Transparency System

Text

Novavax AB, Uppsala, Sweden

01/01/2017 EU funding: 733073 - Multivivax - Development of Effective Vaccines Against Multiple Lifecycle Stages of Plasmodium Vivax Malaria
01/01/2017 EU funding: 733273 - Optimalvax - Optimizing a Deployable High Efficacy Malaria Vaccine
01/01/2017 EU funding (€139,823): 733273 - Optimalvax - Optimizing a Deployable High Efficacy Malaria Vaccine
01/01/2017 EU funding (€50,675): 733073 - Multivivax - Development of Effective Vaccines Against Multiple Lifecycle Stages of Plasmodium Vivax Malaria
CSV export

Investigative Journalism

Uncover International Corporate Connections with our Free Investigative-Account

This filing was translated from to English. The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Novavax AB, Uppsala, Sweden.

Creative Commons License The visualizations for "Novavax AB - 4 EU fundings (total €190,498): 733273 - Optimalvax - Optimizing a Deployable High Efficacy Malaria Vaccine …" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.
Close